Journal article icon

Journal article

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial

Abstract:

Background: Intradermal MVA85A, a candidate vaccine against tuberculosis, induces high amounts of Ag85A-specific CD4 T cells in adults who have already received the BCG vaccine, but aerosol delivery of this vaccine might offer immunological and logistical advantages. We did a phase 1 double-blind trial to compare the safety and immunogenicity of aerosol-administered and intradermally administered MVA85A. Methods: In this phase 1, double-blind, proof-of-concept trial, 24 eligible BCG-vaccinate...

Expand abstract

Actions


Access Document


Authors


Harris, SA More by this author
Thomas, ZRM More by this author
Griffiths, K More by this author
Expand authors...
Publisher:
Lancet Publishing Group
Journal:
The Lancet Infectious Diseases
Volume:
14
Issue:
10
Pages:
939-946
Publication date:
2014-10-01
DOI:
EISSN:
1474-4457
ISSN:
1473-3099
URN:
uuid:fcfe9fe6-b77c-4269-95ab-18fd1d0fa2fa
Source identifiers:
489057
Local pid:
pubs:489057
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP